PLM-102

PLM-102 is an orally bioavailable small molecule inhibitor of the Proviral Insertion site in Moloney murine leukemia virus (PIM) kinases, specifically targeting PIM1, PIM2, and PIM3. Developed at the M.D. Anderson Cancer Center, PLM-102 was designed to treat hematologic malignancies, particularly relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). PIM kinases are frequently overexpressed in these cancers and play a critical role in promoting cell survival, proliferation, and resistance to apoptosis through the phosphorylation of various downstream targets in the JAK/STAT and PI3K/AKT/mTOR pathways. By inhibiting PIM kinases, PLM-102 aims to induce cell cycle arrest and apoptosis in leukemic cells. Clinical development reached Phase I but was terminated by the sponsor due to a change in the development plan.